Author [ref]

Center

Year

Interval

N

postop IMRT

CT

T3/4

N>/=2

lll/lV

LRC

D M F S

O A S


Postop

Definitive

Postop

Definitive

Postop

Definitive


Eisbruch et al [3]

U of MI

2004

19972002

27

most postop

na

na

na

na

59% (3y)

na

na

na

na

na

Yao et al [4]

U of Iowa

2007

200105

55

49 (89%)

11%

56%

36%

91%

85% (3y)

na

89% (3y)

na

68% (3y)

na

Studer et al [5]∗ 
U of Zurich

2007

200207

58

28 (48%)

78%

69%

28%

62%

91% (2y)

43% (2y)

95% (2y)

85% (2y)

83% (2y)

30% (2y), n = 30

Gomez et al [12]

MSKCC

2009

200006

35

35 (100%)

29%

40%

38%

80%

77% (3y)

none

85% (3y)

na

74% (3y)

none

Chen WC et al [13]

Chiayi, Taiwan

2009

200205

22

22 (100%)

na

na

7 (32%)

100%

64% (3y)

none

na

na

67% (3y)

none

Collan et al [14]

U of Helsinki

2011

20012007

40

40 (100%)

38%

na

na

na

na

none

na

na

75% (3y)

none

Sher D et al [15]

DFCI

2011

200409

42

30 (71%)

~76%

45%

30%

64%

91% (2y)

64% (2y)

94% (2y)

83% (2y)

85% (2y)

63% (2y), n = 12

Daly M et al [16]

Stanford UMC

2011

200209

37

30 (81%)

68%

54%

46%

57%

53% (3y)

60% (3y)

81% (3y)

71% (3y)

60% (3y)

57% (3y), n = 7

own cohort

U of Zurich

2012

20022011

160
 99 (62%) ∗∗ 
72%

40%

77%

68%

84% (4y)

40% (4y)

90% (4y)

85% (4y)

81% (4y)

38% (4y), n = 44

 (∗): included in the recent analysis.
 (∗∗): included all patients with R01 status (excluded 17 operated patients with macroscopic disease after surgery.
 U: University Hospital.
 MSKCC: Memorial SloanKettering Cancer Center.
 DFCI: DanaFarber Cancer institute.
 UMC: University Medical Center.
 CT: Chemotherapy.
 LRC: locoregional control.
 DMFS: distant metastasis free survival.
 OAS: overall survival.